Keros Therapeutics KROS 深 滬
等待開盤 09-30 09:30:00 美东时间
15.95
-0.100
-0.62%
華盛通- 最 高16.2961
- 今 開16.11
- 成交量 27.13万股
- 最 低 15.67
- 昨 收 16.05
- 總市值 6.48亿
- 52周最高 72.37
- 市盈率 靜 --
- 換手率 0.67%
- 52周最低 9.12
- 委 比 24.53%
- 總股本 4061.54万
- 歷史最高 88.80
- 量 比 1.04
- 振 幅 3.90%
- 歷史最低 9.12
- 每 手 1
- 風險率 11.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
Boston-based biopharmaceutical company Keros Therapeutics presented data from its Phase 1 trial of KER-065, a modified activin receptor ligand trap, at the American Society of Bone and Mineral Research Annual Meeting. The trial demonstrated KER-065's safety, tolerability, and potential to improve bone mineral density in healthy male volunteers. KER-065 inhibits myostatin and activin A signaling, targeting conditions like Duchenne muscular dystrop...
09-08 12:00
Keros Therapeutics CEO to Speak at Healthcare Conferences
An update from Keros Therapeutics ( ($KROS) ) is now available. On August 28, 2...
08-29 04:36
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
<p>Keros Therapeutics' CEO, Jasbir S. Seehra, Ph.D., will present at the 2025 Wells Fargo Healthcare Conference on September 4, 2025, and the H.C. Wainwright Global Investment Conference on September 9, 2025. Sessions include a fireside chat and a corporate presentation. Archived replays will be available on the company's Investor Relations page. Keros is a biopharmaceutical company developing novel therapeutics targeting TGF-β signaling-related ...
08-28 20:01
Keros Therapeutics Reveals The FDA Granted Orphan Drug Designation For KER-065 For The Treatment Of Duchenne Muscular Dystrophy
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a
08-20 21:50
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
Lexington, Mass., August 20, 2025 - Keros Therapeutics, Inc. announced that the U.S. FDA granted Orphan Drug designation for KER-065 to treat Duchenne muscular dystrophy (DMD). This designation recognizes the significant unmet need for DMD patients and provides potential benefits like tax credits, reduced fees, and market exclusivity. KER-065 is a novel ligand trap targeting myostatin and activin A to improve muscle regeneration and strength. DMD...
08-20 13:48
Keros Therapeutics Announces Strategic Realignment To Reallocate Resources Towards Development Of Its Key Clinical Program, KER-065; Discontinues Development of Cibotercept (KER-012)
Company Discontinuing Development of Cibotercept (KER-012)Announces Board and Leadership Changes Designed to Support Streamlined Operational Structureand Strategic RealignmentLEXINGTON, Mass., Aug. 06, 2025 (GLOBE
08-07 04:59
Keros Therapeutics Q2 EPS $(0.76) Beats $(1.11) Estimate, Sales $18.168M Beat $2.767M Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(1.11) by 31.78 percent. This is a 39.2 percent increase over losses of $(1.25) per share from
08-07 04:45
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
Keros Therapeutics has discontinued development of cibotercept (KER-012) and realigned its operations to focus on its lead clinical program, KER-065, for Duchenne muscular dystrophy. The company has also made leadership changes, including Jasbir S. Seehra becoming President, Jean-Jacques Bienaimé as Board Chair, and Christopher Rovaldi stepping down as COO. These changes aim to support the streamlined focus on advancing KER-065.
08-06 20:15
Kratos, Champion Tire & Wheel Launch Industry-First Automated Truck Platoon to Support NASCAR Brickyard 400 Logistics
Kratos Defense & Security Solutions and Champion Tire & Wheel successfully deployed the first automated truck platoon to support the Brickyard 400, using driverless technology for motorsports logistics. Two tractor-trailers, equipped with advanced V2V communications and automation, transported tires and equipment between Ohio and Indiana, demonstrating how this technology can enhance commercial logistics efficiency and scalability. The deployment...
07-29 12:00
Keros Therapeutics Announces First Patient Dosed In Phase 3 RENEW Clinical Trial Of Elritercept In Adults With Transfusion-Dependent Anemia With Very Low, Low, Or Intermediate Risk MDS
Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked
07-17 20:16
